Xencor Inc
NASDAQ:XNCR

  • LAST PRICE
    23.5400
  • TODAY'S CHANGE (%)
    -0.1200 (-0.5072%)
  • Bid / Lots
    23.0900/ 5
  • Ask / Lots
    23.4900/ 5
  • Open / Previous Close
    23.5100 / 23.6600
  • Day Range
    23.4450
    24.2100
  • 52 Week Range
    16.4900
    28.9600
  • Volume
    446,904

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 2 hours ago by MT Newswires
      Companies Mentioned: XNCR
      04:09 PM EDT, 05/09/2024 (MT Newswires) -- ...

    • 2 hours ago by Business Wire
      Companies Mentioned: XNCR

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights.

    • 2 hours ago by Dow Jones
      Companies Mentioned: XNCR
      (Unaudited) Cash, cash equivalents and marketable debt securities - current $ 491,401 $ 551,515 Other current assets 70,851 71,645 Marketable debt securities - long term 155,342 145,892 Other long term assets 166,661 183,640 --------- ---------- Total assets $ 884,255 $ 952,692 ========= ========== Total current liabilities 79,402 84,709 Deferred income - long term 113,367 125,183 Other long term liabilities 79,299 73,667 --------- ---------- Total liabilities 272,068 283,559 Total stockholders' equity 612,187 669,133 --------- ---------- Total liabilities and stockholders' equity $ 884,255 $ 952,692 ========= ========== Xencor, Inc. Consolidated Statements of Loss and Comprehensive Loss (in thousands, except share and per share data) Three months Ended March 31, ---------------------------------- 2024 2023 ------------ ----------- (Unaudited) Revenue $ 12,805 $ 18,962 ------------ ----------- Operating expenses Research and development 56,873 65,552 General and administrative 13,787 14,154 ------------ ----------- Total operating expenses 70,660 79,706 ------------ ----------- Loss from operations (57,855) (60,744) Other income (expense), net (10,854) (19) ------------ ----------- Loss before income tax (68,709) (60,763) Income tax expense -- -- ------------ ----------- Net loss (68,709) (60,763) Net loss attributable to non-controlling interest (676) -- ------------ ----------- Net loss attributable to Xencor, Inc. (68,033) (60,763) Other comprehensive income (loss): Net unrealized gain (loss) on marketable debt securities available-for-sale (1,445) 3,327 ------------ ----------- Comprehensive loss attributable to Xencor, Inc. $ (69,478) $ (57,436) ============ =========== Net loss per common share attributable to Xencor, Inc.: Basic and Diluted $ (1.11) $ (1.02) ============ =========== Weighted average common shares used to compute net loss per share attributable to Xencor, Inc. Basic and Diluted 61,212,324 59,771,674 ============ ===========

    • 2 hours ago by Dow Jones
      Companies Mentioned: XNCR
      PASADENA, Calif.--(BUSINESS WIRE)--May 09, 2024--
      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights.

  • Apr 16, 2024

Peers Headlines